Document is current

Article History

Received: 24 November 2024

Accepted: 13 March 2025

First Online: 19 March 2025

Declarations

:

: H.L.M. has received reimbursement of participation fees for scientific meetings and continuing medical education events from the following companies: Ferring, Pfizer, Sandoz/Hexal, Novo Nordisk, IPSEN, Merck Serono, and Rhythm Pharmaceuticals. He has received reimbursement of travel expenses from Merck Serono, Rhythm Pharmaceuticals and IPSEN and lecture honoraria from Pfizer and Rhythm Pharmaceuticals. The other authors declared no conflict of interest.

: The study protocol of KRANIOPHARYNGEOM 2000 was proven and accepted by the ethical committee of the University of Würzburg, Germany [140/99]; KRANIOPHARYNGEOM 2007 was proven and accepted by the ethical committee of the University of Würzburg, Germany [96/06]; the protocol of KRANIOPHARYNGEOM Registry 2019 was proven and accepted by the ethical committee of the Carl von Ossietzky Universität Oldenburg, Germany [2019-046]. The study protocol of this project was approved by ethical committee of the Carl von Ossietzky Universität Oldenburg, Germany [2023-006] The studies comply with the Declaration of Helsinki.

: All custodians were informed according to the study protocols and gave written informed consent.